HIV-Associated Lipodystrophy Syndrome
"HIV-Associated Lipodystrophy Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
Descriptor ID |
D039682
|
MeSH Number(s) |
C02.782.815.616.400.400 C02.800.801.400.400 C17.800.849.391.400 C18.452.584.625.400 C18.452.880.391.400 C20.673.480.400
|
Concept/Terms |
HIV-Associated Lipodystrophy Syndrome- HIV-Associated Lipodystrophy Syndrome
- HIV Associated Lipodystrophy Syndrome
- Lipodystrophy Syndrome, HIV-Associated
- HIV Lipodystrophy Syndrome
- HIV-Associated Lipodystrophy
- HIV Associated Lipodystrophy
- Lipodystrophy, HIV-Associated
- Lipodystrophy Syndrome, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV-Associated Lipodystrophy Syndrome".
Below are MeSH descriptors whose meaning is more specific than "HIV-Associated Lipodystrophy Syndrome".
This graph shows the total number of publications written about "HIV-Associated Lipodystrophy Syndrome" by people in this website by year, and whether "HIV-Associated Lipodystrophy Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2005 | 0 | 1 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV-Associated Lipodystrophy Syndrome" by people in Profiles.
-
COHORT PROFILE: The Complications of Long-Term Antiretroviral Therapy study in Uganda (CoLTART), a prospective clinical cohort. AIDS Res Ther. 2017; 14:26.
-
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study. Lancet HIV. 2017 01; 4(1):e13-e20.
-
HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):839-44.
-
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child. 2013 Apr; 98(4):258-64.
-
Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005; 65(16):2309-36.